Hematology/Oncology

• Meeting News Coverage Perspective

• PD-L1 targeted antibody induced tumor shrinkage in several cancer types

• May 17, 2013
• The investigational drug MPDL3280A, an engineered PD-L1 targeted antibody, significantly improved tumor shrinkage rates in patients with locally advanced...More »

• In the Journals

• Alzheimer’s disease risk significantly reduced among older NMSC patients

• May 17, 2013
• Patients aged 70 years or older with nonmelanoma skin cancer had a significantly reduced risk for developing Alzheimer’s disease compared with...More »

• In the Journals

• MEK inhibitor shows activity in NRAS-mutated melanoma

• May 17, 2013
• Twenty percent of patients with NRAS-mutated melanoma treated with MEK162 demonstrated partial response, according to results of an open-label, phase 2...More »

• CME

• Electro-Gene Therapy with IL-12 Plasmid in Metastatic Melanoma

• This activity will discuss the safety, efficacy, and side effects of IL-12, as shown in Phase I and Phase II studies…...More »
• This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

• In the Journals

• Indoor tanning more prevalent among young, fair-featured women in Italy

• May 7, 2013
• Overall tanning bed use in Italy was 20% and higher among women, young and more educated people following introduction of access restrictions including a...More »

• FDA proposes new tanning bed requirements, including skin cancer warnings

• May 6, 2013
• The FDA issued a proposal on Monday that would reclassify sunlamp products from a low-risk device (class I) to a moderate-risk device (class II) and would...More »

• In the Journals

• Prolonged suture support led to decreased scar spread

• May 6, 2013
• Prolonged intradermal suture support of excision sites among patients with truncal skin cancer led to significantly decreased scar spread, according to...More »

• In the Journals

• Most nonmelanoma skin cancers treated surgically, regardless of life expectancy

• May 2, 2013
• Regardless of a patient’s life expectancy, most nonmelanoma skin cancers were treated surgically, according to recent study results.
  “It can be...More »

• CME

• Does Biochemotherapy Have a Role in Adjuvant Therapy?

• This activity will discuss the role of biochemotherapy in adjuvant therapy when treating high-risk melanoma patients…...More »
• This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

• CME

• Debate: “Interferon Sensitivity”: Adjuvant IFN Should Be Used Only in Patients with Ulceration and/or Microscopic Nodal Disease

• This activity will feature two experts debating the efficacy of high-dose, intermediate-dose and low-dose interferon in melanoma patients in various disease stages and with certain characteristics,…...More »
• This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!